An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

Phase 2 Unknown 29 enrolled IRCCS San Raffaele Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

To assess whether nivolumab+nab-paclitaxel combination results in patients with muscle-invasive bladder cancer

Met primary endpoint

paper The trial met its primary end point: 10 patients (32.3%; 95% CI, 16.7 to 51.4) achieved an ypT0N0 response. PMID 39241203 ↗

Evaluation	Drug	Modality	Dose	Route
Subject	Nab-paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	Nivolumab	Monoclonal antibody	360 mg	Intravenous